Korro Bio Inc (KRRO) Financiero

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.